6-K

Haleon plc (HLN)

6-K 2025-09-22 For: 2025-09-22
View Original
Added on April 05, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form<br>20-F ☒ Form<br>40-F ☐

EXHIBIT INDEX

Exhibit Number Description
99.1 22<br>September 2025- “Director/PDMR<br>Shareholding”

99.1

Haleon plc: Director/PDMR Shareholding

22 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 19 September 2025, the Company received notification of the following transactions as detailed below.

1 Details of the person discharging managerial responsibilities /<br>person closely associated
a) Name Tamara<br>Rogers
2 Reason for the notification
a) Position/status Chief<br>Marketing Officer - PDMR
b) Initial notification /Amendment Initial<br>Notification
3 Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor
a) Name Haleon<br>plc
b) LEI 549300PSB3WWEODCUP19
4 Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
a) Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification<br>code Ordinary Shares of 0.01 each<br><br> <br><br><br>GB00BMX86B70
b) Nature of the transaction Acquisition of Ordinary Shares in respect of dividend<br>reinvestment.
c) Price(s) and volume(s)
Volume(s)
5
d) Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br><br><br><br>- Price N/A
e) Date of the transaction 18<br>September 2025
f) Place of the transaction London<br>Stock Exchange (XLON)

All values are in British Pounds.

1 Details of the person discharging managerial responsibilities /<br>person closely associated
a) Name Alan Stewart
2 Reason for the notification
a) Position/status Independent Non-Executive Director - PDMR
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor
a) Name Haleon plc
b) LEI 549300PSB3WWEODCUP19
4 Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted
a) Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification code Ordinary Shares of 0.01 each<br><br><br> <br><br><br>GB00BMX86B70
b) Nature of the transaction Acquisition of Ordinary Shares as a result of dividend<br>reinvestment
c) Price(s) and volume(s)
Volume(s)
214
d) Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br><br><br><br>- Price N/A
e) Date of the transaction 18 September 2025
f) Place of the transaction London Stock Exchange (XLON)

All values are in British Pounds.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HALEON PLC<br><br><br>(Registrant)
Date: September 22,<br>2025 By: /s/<br>Amanda Mellor
Name: Amanda<br>Mellor
Title: Company<br>Secretary